JUBILANT PHARMA LIMITED

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to our customers across geographies. They have organized their business into three segments: ‘Specialty pharmaceuticals’ segment, ‘CDMO’ segment, and Active pharmaceutical ingredients segment.  The Company supplies its products and services to customers in 85+ countries. They have four manufacturing facilities in North America and two in India and few Research and development Centres in North America and India. Additionally, they have a distribution network of more than 45 radiopharmacies in the USA.

Recently, on 19 April 2021, they have announced the development of a novel oral formulation of Remdesivir with successful completion of safety and absorption studies in animals and healthy human volunteers. The press has also released information regarding the launch of Sulfate tablets in the U.S market in November 2020 by Jubilant Pharma ltd. along with Aavis Pharmaceuticals. In August 2020, they had announced the launch of ‘JUBI-R’ in India to combat the COVID-19.

The shareholding pattern of the company consists of: FIIs having 46.51% shares, DIIs having 4.16% shares, Public having 49.26% shares and Others having 0.07% shares.

For the quarter ending 31-03-2021, the company has recorded a revenue of Rs.1579.78 Cr. which is slightly less against Rs.1771.34 Cr. in the last quarter. Their total income stands at Rs.1586.47 Cr. against Rs.1774.93 Cr. in the last quarter. The profit after tax earned by the company is Rs.213.65 Cr. which is 31% less than the last quarter which was Rs.309.83.

Considering, the statement published by the company, they have shown a decline in their performance over the last quarter as well as the last financial year. This could be attributed to a number of reasons, but despite the COVID-19 led challenges, the company continued to experience strong demand across most of its businesses.